1.The default and some causes when the use of DMPA for woman of reproductive age in Viet Nam
Journal of Practical Medicine 2004;478(4):52-55
The investigation was performed with 871 users of DMPA. Among them 516 had been use and 355 defaults. DMPA was accepted because of the convenience for use (62%), the high effectiveness (56%), no side effect, no adverse reation for sexual activity. The rate of defaults was from 10-70%, depending on the province, the time.. 80.2% by the cause of side effects, in which amenorrhia 33.2% and menstrual disorder 43.4%.
Women
;
Aniline Compounds/adverse effects
2.Assessment of side - effects of DMPA
Journal of Medical Research 2003;26(6):135-140
871 women who have using DMPA contraceptive injection from 1997 to 2001 in 3 provinces of Yen Bai, Thanh Hoa, Dong Thap (each district for province and a total of 13 communes) were assessed. 88.4% of subjects had had side effects, among them 40.1% amenorrhoae, 25.1% dysmenorrhoae, 19.5% weight gain, 22% head pain, 13.3% nausea. Two typical signs are facial skin darkening and vaginal dryness. Menstruation disorder and amenorrhoae are positively proportional and vaginal dryness and facial skin darkening are inversely proportional with age, the number of pregnancy and of pregnancy termination.
Aniline Compounds
;
adverse effects
;
drugs
3.Study on the relationship between the opacity of lens and the levels of 2, 6-dinitro-4-amino-toluene (DNAT) in the urine of workers exposed to trinitrotoluene(TNT).
Zhongde ZHU ; Zhilan LI ; Fatai MI ; Suqin LIAN ; Pengcheng DONG ; Yuhua WU ; Xiaohua SUN
Chinese Journal of Industrial Hygiene and Occupational Diseases 2002;20(1):42-43
OBJECTIVETo find out the relationship between the opacity in lens and the contents of 2,6-dinitro-4-amino-toluene(DNAT) in the urine of exposed workers.
METHODSTesting the exposed worker's lens and measuring the contents of DNAT in the urine after work.
RESULTSWhen the opacity of the lens occurred, the contents of DNAT in the urine(2.38 mg/L) of workers exposed to TNT were significantly higher than those without opacity in lens(1.44 mg/L) (P < 0.05).
CONCLUSIONThe severity of opacity of lens increased with the contents of DNAT raised in the urine. The threshold value suggested by ILO is not applicable to Chinese occupational population, which recommends the contents of DNAT(30 mg/L) in the urine for the workers exposed to TNT as biological occupational exposed limits.
Aniline Compounds ; urine ; Cataract ; chemically induced ; Environmental Monitoring ; Humans ; Occupational Exposure ; adverse effects ; Trinitrotoluene ; metabolism
4.AZD9291-induced Acute Interstitial Lung Disease.
Ke-Ke NIE ; Xiao ZOU ; Chuan-Xin GENG ; Ling ZHANG ; Shi-Chao LIU ; Chun-Ling ZHANG ; You-Xin JI
Chinese Medical Journal 2016;129(12):1507-1508
5.Osimertinib Re-challenge for EGFR-mutant NSCLC after Osimertinib-induced Interstitial Lung Disease: A Case Report.
Junjie GU ; Fan BAI ; Lan SONG ; Yingyi WANG
Chinese Journal of Lung Cancer 2021;24(11):804-807
Osimertinib-induced interstitial lung disease (ILD) is an uncommon, but fatal pulmonary toxicity in some patients. We report a case of a 64-year-old male with stage IV adeno-non-small cell lung cancer (NSCLC) harboring an exon 19 deletion in the epidermal growth factor receptor (EGFR) treated with osimertinib 80 mg/d for first-line targeted therapy. On day 60 after initiating treatment of osimertinib, the patient developed ILD. Osimertinib was discontinued immediately and oral prednisone 60 mg/d was initiated, ILD improved within 13 d. After balancing the risk and benefit, osimertinib was restarted concurrently with prednisone. The patient showed neither disease progression nor a recurrence of ILD for more than 16 months. Based on our case and literature review, retreatment with osimertinib under steroid coverage could be considered as an effective treatment option after careful risk-benefit assessment for patients with EGFR-mutant NSCLC.
.
Acrylamides/therapeutic use*
;
Aniline Compounds/therapeutic use*
;
Carcinoma, Non-Small-Cell Lung/genetics*
;
ErbB Receptors/genetics*
;
Humans
;
Lung Diseases, Interstitial/genetics*
;
Lung Neoplasms/genetics*
;
Male
;
Middle Aged
;
Prednisone
;
Protein Kinase Inhibitors/adverse effects*
6.Protective effect of ligustilide against glutamate-induced apoptosis in PC12 cells.
Qian WU ; Ning WANG ; Yan WANG ; Guang-Yun WANG ; Xin-Xin PIAO
Acta Pharmaceutica Sinica 2015;50(2):162-168
To investigate the neuroprotective of ligustilide (LIG) against glutamate-induced apoptosis of PC12 cells, cell viability were examined by MTT assay. Flow cytometry was applied to assay cell apoptosis rate. Intracellular calcium concentration was measured by using fluorescent dye Fluo-3/AM. Cytochrome C (Cyt C), Caspase-3, Bax and Bcl-2 protein expression were assayed by western blot. The results showed that glutamate is cytotoxic with an inhibitory concentration 50 (ID50) of 15 mmol · L(-1). Pretreatment with LIG (1, 5, 15 μmol · L(-1)) significantly improved cell viability. The apoptosis rate in glutamate-induced PC12 cells was 13.39%, and decreased in the presence of LIG (1, 5, 15 μmol · L(-1)) by 9.06%, 6.48%, 3.82%, separately. Extracellular accumulation of Ca2+ induced by glutamate were significantly reduced by LIG. The results of western blot manifested that pretreatment LIG could decrease the release of Cyt C from mitochondria, down-regulate Caspase-3 protein expression and up-regulate Bcl-2/Bax ratio, thereby protects PC12 cells from apoptosis. In summary, LIG had protective effect on glutamate-induced apoptosis in PC12 cells through attenuating the increase in intracellular Ca2+ concentration, and inhibiting the release of Cyt C from mitochondria to cytoplasm.
4-Butyrolactone
;
analogs & derivatives
;
pharmacology
;
Aniline Compounds
;
Animals
;
Apoptosis
;
drug effects
;
Apoptosis Regulatory Proteins
;
Calcium
;
metabolism
;
Caspase 3
;
metabolism
;
Cell Survival
;
Cytochromes c
;
metabolism
;
Glutamic Acid
;
adverse effects
;
Mitochondria
;
metabolism
;
PC12 Cells
;
drug effects
;
Proto-Oncogene Proteins c-bcl-2
;
metabolism
;
Rats
;
Xanthenes
;
bcl-2-Associated X Protein
;
metabolism